E815
TEAS SECTION 8 & 15 RECEIVED
09/06/2026
Voltar para busca
Dado oficial do USPTO
UBRELVY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
10/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
07/11/2018
Data de registro
09/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/06/2020
Última transação
10/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
22/01/2020
Primeiro uso no comércio
22/01/2020
Código do desenho
3
Tipo de titular
99
Localização do titular
Dublin 17, IE
Examinador
FATHY, DOMINIC
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "UBRELVY" below two wavy lines, both of which generally begin above the "E" in "UBRELVY" and extend in opposite directions.
Titulares e representantes
Titulares
Allergan Pharmaceuticals International Limited
Allergan Pharmaceuticals International Limited
Representantes
Matthew O. Brady
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations used in connection with anti-agingfor use in the treatment of glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfor facial aesthetic surgeryfacial aesthetic reconstructionbreast aesthetic treatment procedures; topical antibioticsanti-inflammatoryanti-infectiveanti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutionsartificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disordersmuscle dystoniasmooth muscle disordersautonomic nerve disordersheadacheshyperhidrosissports injuriescerebral palsyspasmstremors and pain; dermatological formulationsmedicated dry skin lotions and creamsacne medications and medicated skin lightener lotions and creams; Oraltransdermalinjectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiaCNSneurological disordersneurodegenerative disordersdepression; neuroprotective agent; antidepressants; pharmaceuticalsantipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin caremedicated skin cleanserstonersmoisturizersrejuvenatorsrehydrating creamslotions for the face and body
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
09/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
09/06/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/05/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/05/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
20/04/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
20/04/2020
IUAF
USE AMENDMENT FILED
06/04/2020
EISU
TEAS STATEMENT OF USE RECEIVED
06/04/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
30/10/2019
EX1G
SOU EXTENSION 1 GRANTED
28/10/2019
EXT1
SOU EXTENSION 1 FILED
28/10/2019
EEXT
SOU TEAS EXTENSION RECEIVED
28/10/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
30/04/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/03/2019
PUBO
PUBLISHED FOR OPPOSITION
05/03/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/01/2019
DOCK
ASSIGNED TO EXAMINER
24/01/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
27/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/11/2018
NWAP
NEW APPLICATION ENTERED
10/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace UBRELVY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.